Valgen Medtech Announces the Completion of its Round B Financing, in Which the Lead Investors Were DCP Capital and Sequoia Capital
Valgen Medtech
(Hangzhou, China; May 6, 2021) Hangzhou Valgen Medtech Co., Ltd. (Valgen Medtech), a subsidiary of Dinova Medtech Group (Dinova Medtech), announces that it had recently completed Round B financing. This round of financing amounted to hundreds of millions of US dollars and the money will be mainly used for technological innovation and product development in the field of mitral valve and tricuspid valve disease treatment. DCP Capital and Sequoia China were lead investors, and Venus Medtech, Lake Bleu Capital, China Life Big Health Fund, and Ascendum Capital were co-investors. Qiming Venture Partners, as an old shareholder, continued to raise its stakes.
Dinova Medtech is a professional investment and operation management company group in the innovative life technology industry. It is committed to the discovery, investment, and integration of ground-breaking innovative new medical technology projects to provide solutions to major diseases that seriously threaten human health but lack effective therapies.
Valgen Medtech was founded in 2015 and is committed to the R&D of mitral valve and tricuspid valve related treatment technologies. Mitral regurgitation is the most common valvular disease of the heart (VDH). It is estimated that there are more than 10 million moderate to severe MD patients, including several millions of severe MD patients who need intervention in China. However, half of these patients cannot be effectively treated due to old age, poor cardiac function, concomitant malfunction of other organs, and/or other reasons. In recent years, transcatheter mitral valve interventional procedure techniques are rapidly developing with the continual improvement of interventional therapeutic devices and increased experience gained by interventional surgeons.
As a leading company in the field, Valgen Medtech is committed to the R&D of a full set of technologies for minimally-invasive procedures on mitral valve and tricuspid valve. Its products mainly include:
* The first Chinese transapical interventional product (MitralStitch®) for the treatment of mitral regurgitation, successfully used for human clinical studies in 2018, presently in the pre-marketing registration clinical study stage;
* The development of DragonFly-T™,™ the first Chinese transfemoral tricuspid valve repair device, proceeded to human clinical studies stage in 2020, and the safety and effectiveness of the product have been verified in 10 exploratory clinical studies.
* The development of DragonFly-T™, the first Chinese transfemoral tricuspid valve repair device, proceeded to human clinical studies stage in 2020, and the safety and effectiveness of the product have been verified in 10 exploratory clinical studies.
The DragonFl™Transcatheter Mitral Valve Repair System has filled the gap between China and other countries in transfemoral mitral valve procedure devices. As a result, Chinese companies and top international companies are now at the same level in the development of interventional mitral valve devices.
Comments by Mr. Zhao Yiwei, Chairman of the Board, Dinova Medtech: "The joint efforts of hospitals and medical device manufacturers have created extraordinary values. Valgen Medtech, a company driven by innovation, has developed the first Chinese transapical and transfemoral interventional procedure technology for mitral valve diseases, thus securing its position as a pioneer in the field of structural heart diseases in the world. Its a pleasure to win the trust of top investors, including DCP Capital and Sequoia China. Valgen Medtech will continue to promote the development and commercialization of mitral valve and tricuspid valve interventional medical devices to provide doctors and patients worldwide with innovative minimally-invasive interventional procedure solutions."
Comments by Mr. Shen Nanpeng, Executive Partner of Sequoia Capital, founder and executive partner of Sequoia Capital China Fund: The diagnosis and treatment of structural heart diseases are of great importance in life science and health and a significant developmental direction continuously attracting the attention and support of Sequoia Capital China Fund. Valgen Medtech is far ahead of others in business deployment in mitral valve and tricuspid valve disease therapies. Many of its products have filled the gap between China and other countries in the field. As one of the lead investors in this round of financing, we sincerely hope that Valgen Medtech can promote the progress of product development to benefit more and more Chinese and foreign patients suffering from cardiovascular disease.
Comments by Mr. Liu Haifeng, Chairman of the Board of DCP Capital: "Dinova Medtech is the most successful Chinese ground-breaking medical technology innovation platform. Since its foundation, Dinova Medtech has successfully run a number of top companies in the field of minimally-invasive interventional procedures for cardiovascular disease. The achievements attained by Valgen Medtech in the field of structural heart disease fully demonstrate the prospective knowledge and predictions of the Dinova Medtech management team. We are glad to be a cooperative partner of Valgen Medtech and will spare no effort in assisting Valgen Medtech to make greater achievements in the future in line with the company's philosophy "based in China, oriented towards the world".
![](/Public/ueditor/upload/image/20231031/1698718592960090.jpeg)
Valgen Medtech was founded in 2015 by Dinova Medtech Group and is headquartered in Binjiang District, Hangzhou. It has established an R&D base in Shenzhen. It is committed to the R&D of mitral valve and tricuspid valve treatment technologies and the provision of systematic solutions. The Valgen Medtech DragonFly™ Transcatheter Mitral Valve Repair System has filled the gap between China and other countries in transfemoral mitral valve therapeutic devices. The company will continue to promote the development of mitral valve and tricuspid valve procedure devices to benefit the world with products made in China.
![](/Public/ueditor/upload/image/20231031/1698718592189451.jpeg)
DCP Capital is an international private equity institutional investor focusing on the Asian market. The core team at DCP Capital led the private equity investment business of KKR and Morgan Stanley in Asia and brought about outstanding long-term returns from investments spanning multiple periods. DCP Capital received vigorous support from leading international and Chinese long-term institutional investors including sovereign wealth funds, pension funds, donated funds, mother funds, and family funds of many countries.
DCP Capital has invested in a series of groundbreaking PE projects in China over the past 28 years in support of numerous Chinese leading enterprises including Ping An Insurance, Mengniu Dairy, Qingdao Haier, China International Capital Corporation Limited (CICC), Venus Medtech, Tonghua Dongbao, Oriental Yuhong, Yuanfudao, Xingsheng Selected, Simple Love Yogurt, NanFu Battery, COFCO Meat Holdings Limited, Far East Horizon, Hotwon Group, Hengan International, Belle International, Modern Dairy, United Envirotech Ltd., etc. By virtue of its experience in international investment and network of local resources, DCP Capital has accumulated profound industrial expertise and reliable post-investment management capacity. We are looking forward to forming long-term win-win partnership with and creating bright development prospects for our investee companies by adhering to the philosophy of value investing.
![](/Public/ueditor/upload/image/20231031/1698718593742059.jpeg)
Sequoia China is among those private equity institutional investors that made the earliest deployment in the healthcare industry in China. After more than ten years of in-depth investigation and systematic investment deployment, Sequoia China has invested in nearly 200 healthcare companies with distinctive technology profiles and high growth in the healthcare sector covering a wide variety of segments such as innovative drugs, medical devices, healthcare service, precision medical care, and digital health in the past 16 years. More than 30 of the invested companies have completed their IPO on the Chinese A-share market, HK stock market, and US stock market. Sequoia China has always been committed to identifying outstanding venture companies and seeing that they grow to create a better life and greater value for the society and the public.
![](/Public/ueditor/upload/image/20231031/1698718593355919.png)
![](/Public/ueditor/upload/image/20231031/1698718593754457.jpeg)
Related Articles
-
Breakthrough|Valgen Medtech's Transcatheter Hypertrophic Cardiomyopathy (HCM) Ablation Technique Successfully Used for Exploratory Clinical Application in 10 Patients
2023-12-13 -
当西方遇见东方|浙二王建安院士团队与全球结构性心脏病治疗专家就经导管瓣膜介入治疗展开深入技术交流
2023-12-11 -
Big News|Valgen DragonFly™ Transcatheter Mitral Valve Repair System Granted Marketing Approval in China by the NMPA
2023-11-30
![f3_img01.jpg](/Public/Uploads/uploadfile/images/20231018/f3img01-620.jpg)
Follow Valgen Medtech